睿知中国疾病研究地图
候选清单0

正在招募食管鳞状细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  2. 研究中心北京高博医院Beijing GoBroad Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07049185,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC);

    入选标准第 3 条

  3. Radiologically confirmed disease progression after at least 6 months of prior PD-1/PD-L1 inhibitor-based treatment;

    入选标准第 4 条

    Non-sterilized women of childbearing potential and male participants with such partners must agree to use medically approved contraception during and for 3 months after study drug administration. Women must test negative for serum or urine HCG within 7 days prior to first dose and not be breastfeeding.

    入选标准第 10 条

    Discontinued prior PD-1/PD-L1 therapy due to treatment-related toxicity;

    排除标准第 4 条

    Prior exposure to anti-CTLA-4 therapy;

    排除标准第 5 条

    Prior radiotherapy, chemotherapy, or surgery within 4 weeks prior to first study dose (except bone metastasis palliative radiotherapy); biologics within 4 weeks; targeted therapy within 5 half-lives; unresolved toxicities ≥ Grade 2 (except alopecia);

    排除标准第 18 条

    Prior dual immunotherapy with PD-1 and CTLA-4 antibodies;

    排除标准第 21 条

  4. ECOG performance status of 0-1;

    入选标准第 7 条

  5. At least one measurable lesion per RECIST v1.1 criteria;

    入选标准第 5 条

  6. Other malignancies within 5 years (excluding cured skin basal cell carcinoma or cervical carcinoma in situ);

    排除标准第 9 条

    Known immunodeficiency (e.g., HIV); active HBV (HBsAg-positive with HBV DNA ≥ 2000 IU/mL); or active HCV infection;

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07049185,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Willing and able to provide written informed consent;
  2. Aged 18 to 75 years, inclusive;
  3. Histologically or cytologically confirmed unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC);
  4. Radiologically confirmed disease progression after at least 6 months of prior PD-1/PD-L1 inhibitor-based treatment;
  5. At least one measurable lesion per RECIST v1.1 criteria;
  6. Ability to swallow oral medication;
  7. ECOG performance status of 0-1;
  8. Estimated life expectancy ≥12 weeks;
  9. Adequate organ function (without blood transfusion or growth factors within 14 days prior to first dose), including:
  10. Non-sterilized women of childbearing potential and male participants with such partners must agree to use medically approved contraception during and for 3 months after study drug administration. Women must test negative for serum or urine HCG within 7 days prior to first dose and not be breastfeeding.

排除标准:Exclusion Criteria:

  1. Any active autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism); exceptions: childhood asthma fully resolved without treatment or vitiligo;
  2. Currently using immunosuppressive therapy or systemic corticosteroids >10 mg prednisone/day (or equivalent) within 2 weeks prior to enrollment;
  3. History of severe allergic reactions to monoclonal antibodies;
  4. Discontinued prior PD-1/PD-L1 therapy due to treatment-related toxicity;
  5. Prior exposure to anti-CTLA-4 therapy;
  6. History or evidence of interstitial lung disease or active non-infectious pneumonitis;
  7. Known active tuberculosis;
  8. Known CNS metastases, leptomeningeal disease, or spinal cord compression;
  9. Other malignancies within 5 years (excluding cured skin basal cell carcinoma or cervical carcinoma in situ);
  10. Clinically significant cardiac conditions (NYHA ≥ Class II heart failure, unstable angina, MI within 1 year, clinically significant arrhythmias requiring treatment, QTc >450 ms for males or >470 ms for females);
  11. Clinically significant bleeding within 3 months before enrollment or known bleeding tendency (positive fecal occult blood must be followed by endoscopy if persistent);
  12. Tumor invading major blood vessels or deemed likely to invade during the study;
  13. Patients with esophagotracheal or mediastinal fistulas;
  14. Clinically significant pleural/ascitic/pericardial effusion requiring drainage (if resolved and stable after drainage, enrollment is allowed);
  15. Arterial or venous thrombotic events within 6 months (e.g., stroke, DVT, PE);
  16. Known congenital or acquired bleeding disorders;
  17. Abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months;
  18. Prior radiotherapy, chemotherapy, or surgery within 4 weeks prior to first study dose (except bone metastasis palliative radiotherapy); biologics within 4 weeks; targeted therapy within 5 half-lives; unresolved toxicities ≥ Grade 2 (except alopecia);
  19. Active infection or unexplained fever ≥38.5℃ within 7 days prior to first dose;
  20. Known immunodeficiency (e.g., HIV); active HBV (HBsAg-positive with HBV DNA ≥ 2000 IU/mL); or active HCV infection;
  21. Prior dual immunotherapy with PD-1 and CTLA-4 antibodies;
  22. Significant bleeding history within 1 month (e.g., GI bleeding or vasculitis);
  23. Live vaccine administration within 4 weeks prior to or planned during the study;
  24. Other conditions deemed by the investigator to interfere with participation or study results (e.g., substance abuse, psychiatric disorders, severe lab abnormalities, or social/family limitations).

引自 ClinicalTrials.gov, NCT07049185, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07049185,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07049185